Beugnet F, de Vos C, Liebenberg J, Halos L, Larsen D, Fourie J. Efficacy of afoxolaner in a clinical field study in dogs naturally infested with Sarcoptes scabiei. Parasite. 2016;23:26.
Becskei C, De Bock F, Illambas J, Cherni JA, Fourie JJ, Lane M, et al. Efficacy and safety of a novel oral isoxazoline, sarolaner (Simparica™), for the treatment of sarcoptic mange in dogs. Vet Parasitol. 2016;222:56–61.
Lebon W, Beccati M, Bourdeau P, Brement T, Bruet V, Cekiera A, et al. Efficacy of two formulations of afoxolaner (NexGard® and NexGard Spectra®) for the treatment of generalised demodicosis in dogs, in veterinary dermatology referral centers in Europe. Parasit Vectors. 2018;11:506.
Six RH, Becskei C, Mazaleski MM, Fourie JJ, Mahabir SP, Myers MR, et al. Efficacy of sarolaner, a novel oral isoxazoline, against two common mite infestations in dogs: Demodex spp and Otodectes cynotis. Vet Parasitol. 2016;222:62–6.
Taenzler J, Liebenberg J, Roepke RKA, Frénais R, Heckeroth AR. Efficacy of fluralaner administered either orally or topically for the treatment of naturally acquired Sarcoptes scabiei var canis infestation in dogs. Parasit Vectors. 2016;9:392.
McTier TL, Chubb N, Curtis MP, Hedges L, Inskeep GA, Knauer CS, et al. Discovery of sarolaner: A novel, orally administered, broad-spectrum, isoxazoline ectoparasiticide for dogs. Vet Parasitol. 2016;222:3–11.
Shoop WL, Hartline EJ, Gould BR, Waddell ME, Mcdowell RG, Kinney JB, et al. Discovery and mode of action of afoxolaner, a new isoxazoline parasiticide for dogs. Vet Parasitol. 2014;201:179–89.
Gassel M, Wolf C, Noack S, Williams H, Ilg T. The novel isoxazoline ectoparasiticide fluralaner: Selective inhibition of arthropod γ-aminobutyric acid- and L-glutamate-gated chloride channels and insecticidal/acaricidal activity. Insect Biochem Mol Biol. 2014;45:111–24.
Cavalleri D, Murphy M, Gorbea RL, Seewald W, Drake J. Laboratory evaluations of the immediate and sustained effectiveness of lotilaner (Credelio™) against three common species of ticks affecting dogs in Europe. Parasit Vectors. 2017;10:527.
Kryda K, Six RH, Walsh KF, Holzmer SJ, Chapin S, Mahabir SP, et al. Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs. Parasit Vectors. 2019;12:445.
Becskei C, Kryda K, Fias D, Follis SL, Wozniakiewicz M, Mahabir SP, et al. Field efficacy and safety of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against naturally acquired gastrointestinal nematode infections in dogs presented as veterinary patients in Europe and the USA. Parasit Vectors. 2020;13:70.
Becskei C, Kryda K, Thys M, Holzmer S, Bowersock L, Fernandes T, et al. Efficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced ascarid infections in dogs. Parasit Vectors. 2020;13:71.
Becskei C, Thys M, Kryda K, Meyer L, Martorell S, Geurden T, et al. Efficacy of Simparica Trio™, a novel chewable tablet containing sarolaner, moxidectin and pyrantel, against induced hookworm infections in dogs. Parasit Vectors. 2020;13:99.
McTier TL, Six RH, Pullins A, Chapin S, Kryda K, Mahabir SP, et al. Preventive efficacy of oral moxidectin at various doses and dosage regimens against macrocyclic lactone-resistant heartworm (Dirofilaria immitis) strains in dogs. Parasit Vectors. 2019;12:444.
Brown B, Copeman D. Zoonotic importance of parasites in wild dogs caught in the vicinity of Townsville. Aust Vet J. 2003;81:700–2.
Carlisle CH. The incidence of Dirofilaria immitis (heartworm) in dogs in Queensland. Aust Vet J. 1969;45:535–8.
Carlisle CH. Observations on the treatment of Dirofilaria immitis infection in dogs in Brisbane. Aust Vet J. 1970;46:185–9.
Carlisle C, Atwell R. A survey of heartworm in dogs in Australia. Aust Vet J. 1984;61:356–60.
Nguyen C, Koh WL, Casteriano A, Beijerink N, Godfrey C, Brown G, et al. Mosquito-borne heartworm Dirofilaria immitis in dogs from Australia. Parasit Vectors. 2016;9:535.
Smout FA, Skerratt LF, Butler JR, Johnson CN, Congdon BC. Dingoes (Canis dingo Meyer, 1793) continue to be an important reservoir host of Dirofilaria immitis in low density housing areas in Australia. Vet Parasitol. 2016;215:6–10.
Meyer Steiger DB, Ritchie SA, Laurance SGW. Mosquito communities and disease risk influenced by land use change and seasonality in the Australian tropics. Parasit Vectors. 2016;9:387.
Dunsmore JD, Thompson RCA, Bates IA. Prevalence and survival of Toxocara canis eggs in the urban environment of Perth. Australia. Vet Parasitol. 1984;16:303–11.
Jenkins DJ. Toxocara canis in Australia. Adv Parasitol. 2020;109:873–8.
Jenkins DJ, Lievaart JJ, Boufana B, Lett WS, Bradshaw H, Armua-Fernandez MT. Echinococcus granulosus and other intestinal helminths: current status of prevalence and management in rural dogs of eastern Australia. Aust Vet J. 2014;92:292–8.
Morrison P, Stanton R, Pilatti E. Echinococcus granulosus infection in wild dogs in south-eastern New South Wales. Aust Vet J. 1988;65:97–8.
Eppleston KR, Kelman M, Ward MP. Distribution, seasonality and risk factors for tick paralysis in Australian dogs and cats. Vet Parasitol. 2013;196:460–8.
Greay TL, Oskam CL, Gofton AW, Rees RL, Ryan UM, Irwin PJ. A survey of ticks (Acari: Ixodidae) of companion animals in Australia. Parasit Vectors. 2016;9:207.
Jackson J, Beveridge I, Chilton NB, Andrews RH. Distributions of the paralysis ticks Ixodes cornuatus and Ixodes holocyclus in south-eastern Australia. Aust Vet J. 2007;85:420–4.
Barker D, Barker SC. Survey of cases of tick-paralysis and the presence of the eastern paralysis tick, Ixodes holocyclus, and the southern paralysis tick, Ixodes cornuatus, in the Greater Melbourne Area. Aust Vet J. 2020;98:2–10.
Barker SC, Walker AR, Campelo D. A list of the 70 species of Australian ticks; diagnostic guides to and species accounts of Ixodes holocyclus (paralysis tick), Ixodes cornuatus (southern paralysis tick) and Rhipicephalus australis (Australian cattle tick); and consideration of the place of Australia in the evolution of ticks with comments on four controversial ideas. Int J Parasitol. 2014;44:941–53.
Westwood MN, Emery DL, Dhand NK. Clinical presentation and treatment of tick paralysis in dogs and cats in Sydney (2001–2010). Aust Vet J. 2013;91:491–8.
Holland CT. Asymmetrical focal neurological deficits in dogs and cats with naturally occurring tick paralysis (Ixodes holocyclus): 27 cases (1999–2006). Aust Vet J. 2008;86:377–84.
Webster RA, Mills PC, Morton JM. Indications, durations and outcomes of mechanical ventilation in dogs and cats with tick paralysis caused by Ixodes holocyclus: 61 cases (2008–2011). Aust Vet J. 2013;91:233–9.
Atwell RB, Campbell FE, Evans EA. Prospective survey of tick paralysis in dogs. Aust Vet J. 2001;79:412–8.
Padula AM, Leister EM, Webster RA. Tick paralysis in dogs and cats in Australia: treatment and prevention deliverables from 100 years of research. Aust Vet J. 2020;98:53–9.
Awad M. The decline in tick paralysis cases. Centre for Veterinary Education Control & Therapy Series. 2016;5571:30–1.
Prociv P, Croese J. Human enteric infection with Ancylostoma caninum: hookworms reappraised in the light of a “new” zoonosis. Acta Trop. 1996;62:23–44.
Bowman DD, Montgomery SP, Zajac AM, Eberhard ML, Kazacos KR. Hookworms of dogs and cats as agents of cutaneous larva migrans. Trends Parasitol. 2010;26:162–7.
Macpherson CN. The epidemiology and public health importance of toxocariasis: a zoonosis of global importance. Int J Parasitol. 2013;43:999–1008.
Jenkins DJ, Power K. Human hydatidosis in New South Wales and the Australian Capital Territory, 1987–1992. Med J Aust. 1996;164:18–21.
Grattan-Smith PJ, Morris JG, Johnston HM, Yiannikas C, Malik R, Russell R, et al. Clinical and neurophysiological features of tick paralysis. Brain. 1997;120:1975–87.
Simón F, Siles-Lucas M, Morchón R, González-Miguel J, Mellado I, Carretón E, et al. Human and animal dirofilariasis: the emergence of a zoonotic mosaic. Clin Microbiol Rev. 2012;25:507–44.
Diaz JH. Increasing risks of human dirofilariasis in travelers. J Travel Med. 2014;22:116–23.
Mayne P, Song S, Shao R, Burke J, Wang Y, Roberts T. Evidence for Ixodes holocyclus (Acarina: Ixodidae) as a vector for human lyme borreliosis infection in Australia. J Insect Sci. 2014;14:271.
Graves S, Unsworth N, Stenos J. Rickettsioses in Australia. Ann N Y Acad Sci. 2006;1078:74–9.
Graves S, Jackson C, Hussain-Yusuf H, Vincent G, Nguyen C, Stenos J, et al. Ixodes holocyclus tick-transmitted human pathogens in north-eastern New South Wales. Australia. Trop Med Infect Dis. 2016;1:4.
Fisman DN, Laupland KB. The ‛One Healthʼ paradigm: time for infectious diseases clinicians to take note? Can J Infect Dis Med Microbiol. 2010;21:111–4.
Destoumieux-Garzón D, Mavingui P, Boetsch G, Boissier J, Darriet F, Duboz P, et al. The one health concept: 10 years old and a long road ahead. Front Vet Sci. 2018;5:14.
Packianathan R, Hodge A, Bruellke N, Davis K, Maeder S. Comparative speed of kill of sarolaner (Simparica®) and afoxolaner (NexGard®) against induced infestations of Ixodes holocyclus on dogs. Parasit Vectors. 2017;10:98.
Becskei C, Fias D, Mahabir SP, Farkas R. Efficacy of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against natural flea and tick infestations on dogs presented as veterinary patients in Europe. Parasit Vectors. 2020;13:72.
Becskei C, Liebenberg J, Thys M, Mahabir SP. Efficacy of a novel chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against four common tick species infesting dogs in Europe. Parasit Vectors. 2020;13:100.
Kryda K, Mahabir SP, Carter L, Everett WR, Young DR, Meyer L, et al. Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs. Parasit Vectors. 2020;13:57.
Kryda K, Mahabir SP, Chapin S, Holzmer SJ, Bowersock L, Everett WR, et al. Efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced infestations of five common tick species infesting dogs in the USA. Parasit Vectors. 2020;13:77.
Kryda K, Mahabir SP, Inskeep T, Rugg J. Safety and efficacy of a novel oral chewable combination tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against natural flea infestations in client-owned dogs in the USA. Parasit Vectors. 2020;13:98.
Marchiondo AA, Holdsworth PA, Fourie LJ, Rugg D, Kellmann K, Snyder DE. World Association for the Advancement of Veterinary Parasitology (WAAVP) second edition: guidelines for evaluating the efficacy of parasiticides for the treatment, prevention and control of flea and tick infestations on dogs and cats. Vet Parasitol. 2013;194:84–97.
EMEA. Guideline on good clinical practices. VICH Topic GL9 2001. https://vichsec.org/en/guidelines/pharmaceuticals/pharma-efficacy/good-clinical-practice.html. Accessed 23 May 2020.
Australian Pesticides and Veterinary Medicines Authority (APVMA). The WAAVP guideline for fleas and ticks on dogs and cats. https://apvmagovau/node/1040. 2019.
Fisara P, Webster M. A randomized controlled trial of the efficacy of orally administered fluralaner (Bravecto) against induced Ixodes holocyclus (Australian paralysis tick) infestations on dogs. Parasit Vectors. 2015;8:257.
Ilkiw JE, Turner DM, Howlett CR. Infestation in the dog by the paralysis tick Ixodes holocyclus. 1. Clinical and histological findings. Aust Vet J. 1987;64:137–9.
Ross IC. Tick paralysis in the dog. Aust Vet J. 1934;10:182–3.
Ross IC. An experimental study of tick paralysis in Australia. Aust Vet J. 1927;4:310–29.